GCLLSG patients treated with alemtuzumab : results from the CLL 2 H trial of the mutations in fludarabine-refractory CLL

Andrea Schnaiter,Peter Paschka,Marianna Rossi,Thorsten Zenz,Andreas Bühler,Dirk Winkler,Mario Cazzola,Konstanze Döhner,Jennifer Edelmann,Daniel Mertens, Sabrina Kless, Silja Mack,Raymonde Busch,Michael Hallek,Hartmut Döhner,Stephan Stilgenbauer

semanticscholar（2013）

引用 0|浏览0

暂无评分

摘要

Raymonde Busch, Michael Hallek, Hartmut Döhner and Stephan Stilgenbauer Mario Cazzola, Konstanze Döhner, Jennifer Edelmann, Daniel Mertens, Sabrina Kless, Silja Mack, Andrea Schnaiter, Peter Paschka, Marianna Rossi, Thorsten Zenz, Andreas Bühler, Dirk Winkler, GCLLSG patients treated with alemtuzumab: results from the CLL2H trial of the mutations in fludarabine-refractory CLL TP53 , and SF3B1 , NOTCH1

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要